NEXGEL spent the spring buying a surgical-tissue franchise the hydrogel business could not fund on its own, and the first stub quarter after close already shows the distance between that story and the cash account. The April license of Celularity commercial biomaterials, housed in the new BioNX Surgical unit, was sold as a path that roughly triples the top line and turns the company profitable on contact. What arrived instead is a slower surgical rollout, a manufacturing transfer that still sits in New Jersey, and a backlog that has not yet become billings. The equity now prices a going-concern residual, not a completed transformation.
Consumer brands still carry most of the volume. Biomaterial product sales added only eight hundred fourteen thousand in a partial quarter, while branded consumer lines slipped versus the year-ago period. Convertible notes struck at sixty cents, plus a large warrant tail, sit against a share price that has already broken the Nasdaq bid-price floor. Unrestricted cash at mid-year was under half a million, and first-half operations consumed nearly three million of cash. That is not a working-capital squeeze. It is a capital-structure problem wearing a growth headline.
The next several weeks resolve whether BioNX can convert a nearly eight-hundred-thousand backlog and a hospital-channel SilverSeal launch into cash before a September capital vote, a mid-October listing deadline, and a note-registration clock force another recap. Brian Kieser, who already runs Sequence LifeScience, the manufacturing partner and lead investor, is now interim chief executive. The open question is whether that concentration of power speeds the tissue transfer or simply prices the related-party risk the special committee was formed to watch.